We search the world for investment managers and strategies that aim to deliver robust risk-adjusted performance. The people and approaches we discover may not be well known in Canada, but we think they provide something remarkable – access to what’s next. Our job is to cut through all the noise of short term performance and extra risk-taking to discern real talent. Our clients appreciate being first to see compelling new approaches, even though some are complex or are limited in capacity. For more than a decade, the Next Edge management team has provided rare access to unique strategies before they became widely known.
With more than two decades of selecting and monitoring investment managers, Toreigh’s strongest suit is his passion for finding unique investment ideas.
Robert wears many hats; one of his key roles is listening to our clients to understand what’s missing in the marketplace. He works with top advisors and institutions.
David is responsible for the day to day operation of the firm, including product structuring, human resources, compliance and operations.
Cheng is responsible for financial management and reporting of the company and its funds, internal controls, and alongside the COO, David Scobie, operations and compliance.
Michaels 25 year’s options trading experience provides investors with unique exposure to alternative yield solutions.
Eden’s approach represents a progression in Investment solutions, applying options to source Income and returns through strategies not easily accessible to investors, while protecting their capital with hedges designed over his career.
Peter’s main role is providing manager oversight and due diligence while researching and identifying distinct investment opportunities for both retail and institutional investors.
CHICAGO, May 13 (Reuters) – Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who
FOR IMMEDIATE RELEASE TORONTO, MAY 20TH, 2015 – Next Edge Capital Corp. (‘Next Edge’) is pleased to announce that Dr. John Rowsell and Roy Trice will be joining the firm as strategic advisors. With over 60 years of combined investment industry experience, Dr. Rowsell and Mr. Trice have served in many high-level leadership roles
There is no shortage of vitriol being penned that we are in the midst of a Biotech Bubble. Given bubbles of the past, we are eager to not be fooled this time around. Fool me twice, shame on me, right? We’ve learned our lesson from 15 years ago. Optically, bubble signposts we are now proficient